As more biologic and speciality therapies move beyond the clinic and into users’ homes, patient-centric drug delivery is becoming increasingly important (approximately 500,000 patients in England are already receiving homecare medicine services).
As self-administration becomes more common, pharmaceutical companies need to carefully assess whether patients can use treatments correctly, confidently and consistently.
Stephen Roper, Partner, and Edgar Pogna, Director, Life Science at L.E.K. Consulting, investigate.
Designing around everyday patient needs
In a clinical setting, patients benefit from professional guidance, controlled conditions and immediate reassurance, whereas these safeguards may not be present once treatment moves into their home.
Therefore, it is not uncommon for a delivery system that appears straightforward during supervised use to create uncertainty when patients are treating themselves in isolation.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.
